Program
SHR-1819
A development code. Also written as “SHR-1819 Injection Blank Preparation”.
In Jiangsu HengRui Medicine's pipeline, IL-4Rα
. Its studies are mostly in Dermatitis, Atopic · Asthma, led by Jiangsu HengRui Medicine.
Furthest: phase 3, since May 24, 20245 company-led studies, 1 open or runningNext primary completion: Jun 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 51 open or running | phase 3since May 24, 2024 | Aug 29, 2020 | Jun 2027phase 2 · NCT07321951 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
SHR-1819
, phase 3, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 29, 2020First study: phase 1 study in Healthy VolunteersFirst studyNCT04561128 · 42 enrolled · Australia
- Feb 22, 2021Phase 1 study in AsthmaNCT04772365 · 52 enrolled · China
- Sep 19, 2022Phase 2 study in Moderate to Severe Atopic DermatitisNCT05549947 · 158 enrolled · China
- May 24, 2024Phase 3 study in Moderate to Severe Atopic DermatitisNCT06468956 · 652 enrolled · China
- Dec 21, 2025Phase 2 study in Moderate-to-severe Atopic DermatitisNCT07321951 · 201 enrolled · China
Ahead
- Jun 2027Primary completion: phase 2 study in Moderate-to-severe Atopic DermatitisNCT07321951
TargetBeta
“IL-4Rα”the company's pipeline, read by Claude · source
Other programs on IL4R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| dupilumabrule | Sanofi | phase 4 | 93 |
| drotokibart | Jiangsu HengRui Medicine | phase 3 | 8 |
| TQH2722 | Sino Biopharmaceutical | phase 3 | 7 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07321951Moderate-to-severe Atopic Dermatitis · China | 2 | Active, not recruiting | Jun 2027 | 201 |
| NCT06468956Moderate to Severe Atopic Dermatitis · China | 3 | Completed | Aug 26, 2026 | 652 |
| NCT05549947Moderate to Severe Atopic Dermatitis · China | 2 | Completed | Sep 15, 2023 | 158 |
| NCT04772365Asthma · China | 1 | Completed | Dec 10, 2021 | 52 |
| NCT04561128Healthy Volunteers · Australia | 1 | Completed | Mar 7, 2022 | 42 |
How it is read
Names in the registry
- “SHR-1819”, 4 entries
- “SHR-1819 Injection Blank Preparation”, 1 entry
Codes read as this program: SHR1819.
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 3 studies
- Asthma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.